Successful rechallenge with cisplatin following cisplatin induced ischemic cerebrovascular accident in a patient with small cell lung cancer
journal contribution
submitted on 2025-05-15, 05:19 and posted on 2025-05-15, 06:15 authored by Farah Rashid, Nabil E. Omar, Hassan Aaekl, Ussama Al Homsi, Alaaeldin ShablakCisplatin is a widely used platinum‐based chemotherapy agent. Its common adverse effects are neuropathy, nephrotoxicity, electrolyte abnormality, and rarely causing thrombotic vascular toxicity. We present a patient known to have small‐cell lung cancer who developed ischemic cerebrovascular accident (CVA) after receiving chemotherapy regimen including cisplatin.
Other Information
Published in: Clinical Case Reports
License: http://creativecommons.org/licenses/by/4.0/
See article on publisher's website: https://dx.doi.org/10.1002/ccr3.6469
Funding
Open Access funding provided by the Qatar National Library.
History
Language
- English
Publisher
WileyPublication Year
- 2022
License statement
This Item is licensed under the Creative Commons Attribution 4.0 International License.Institution affiliated with
- Hamad Medical Corporation
- Hamad General Hospital - HMC
- National Center for Cancer Care and Research - HMC
